| 臺大學術典藏 |
2021-11-24T05:47:40Z |
Seroprevalence of Aspergillus IgG and disease prevalence of chronic pulmonary aspergillosis in a country with intermediate burden of tuberculosis: a prospective observational study
|
Lee, M-R; Huang, H-L; Chen, L-C; Yang, H-C; Ko, J-C; Cheng, M-H; Chong, I-W; LI-NA LEE; Wang, J-Y; Dimopoulos, G |
| 臺大學術典藏 |
2021-11-03T05:24:53Z |
Establishing aspergillus-specific igg cut-off level for chronic pulmonary aspergillosis diagnosis: Multicenter prospective cohort study
|
Lee M.-R.; Huang H.-L.; Keng L.-T.; Chang H.-L.; Sheu C.-C.; Fu P.-K.; Wang J.-Y.; Chong I.-W.; Shih J.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2021-11-03T02:33:01Z |
Establishing aspergillus-specific igg cut-off level for chronic pulmonary aspergillosis diagnosis: Multicenter prospective cohort study
|
Lee M.-R.; Huang H.-L.; Keng L.-T.; Chang H.-L.; Sheu C.-C.; Fu P.-K.; Wang J.-Y.; Chong I.-W.; JIN-YUAN SHIH; Yu C.-J. |
| 臺大學術典藏 |
2021-10-27T03:22:14Z |
Lymphadenopathy Associated with Neutralizing Anti-interferon-gamma Autoantibodies Could Have Monoclonal T-cell Proliferation Indistinguishable from Malignant Lymphoma and Treatable by Antibiotics: A Clinicopathologic Study
|
CHANG-TSU YUAN; Wang J.-T.; Sheng W.-H.; Cheng P.-Y.; Kao C.-J.; Wang J.-Y.; Chen C.-Y.; Liau J.-Y.; Tsai J.-H.; Lin Y.-J.; Chen C.-C.; Chen Y.-C.; Chang S.-C.; Wu U.-I. |
| 臺大學術典藏 |
2021-10-04T07:15:47Z |
Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination
|
Lee M.-R.; Yang C.-Y.; Shu C.-C.; Lin C.-K.; Wen Y.-F.; Lee S.-W.; JEN-CHANG KO; Wang J.-Y.; Lee L.-N.; Yu C.-J. |
| 臺大學術典藏 |
2021-10-04T07:15:43Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-10-04T07:15:43Z |
Diabetes Mellitus and Latent Tuberculosis Infection: A Systemic Review and Metaanalysis
|
Lee M.-R.; Huang Y.-P.; Kuo Y.-T.; Luo C.-H.; Shih Y.-J.; Shu C.-C.; Wang J.-Y.; JEN-CHANG KO; Yu C.-J.; Lin H.-H. |
| 臺大學術典藏 |
2021-10-04T07:15:42Z |
Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan
|
Lee M.-R.; Ho C.-M.; Lee C.-H.; Lee M.-C.; Chang L.-Y.; Yu K.-L.; JEN-CHANG KO; Wang J.-Y.; Wang J.-T.; Lee L.-N. |
| 臺大學術典藏 |
2021-10-04T07:15:39Z |
Clinical impact of using fluoroquinolone with low antimycobacterial activity on treatment delay in tuberculosis: Hospital-based and population-based cohort study
|
Lee M.-R.; Lee C.-H.; Wang J.-Y.; Lee S.-W.; JEN-CHANG KO; Lee L.-N. |
| 臺大學術典藏 |
2021-10-04T07:15:39Z |
Outcome of stage IV cancer patients receiving in-hospital cardiopulmonary resuscitation: a population-based cohort study
|
Lee M.-R.; Yu K.-L.; Kuo H.-Y.; Liu T.-H.; JEN-CHANG KO; Tsai J.-S.; Wang J.-Y. |
| 臺大學術典藏 |
2021-10-04T07:15:38Z |
Seroprevalence of Aspergillus IgG and disease prevalence of chronic pulmonary aspergillosis in a country with intermediate burden of tuberculosis: a prospective observational study
|
Lee M.-R.; Huang H.-L.; Chen L.-C.; Yang H.-C.; JEN-CHANG KO; Cheng M.-H.; Chong I.-W.; Lee L.-N.; Wang J.-Y.; Dimopoulos G. |
| 臺大學術典藏 |
2021-10-04T07:15:37Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-10-04T07:15:37Z |
Effect of β-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-27T05:32:38Z |
Lymphadenopathy Associated with Neutralizing Anti-interferon-gamma Autoantibodies Could Have Monoclonal T-cell Proliferation Indistinguishable from Malignant Lymphoma and Treatable by Antibiotics: A Clinicopathologic Study
|
Yuan C.-T.; Wang J.-T.; WANG-HUEI SHENG; Cheng P.-Y.; Kao C.-J.; Wang J.-Y.; Chen C.-Y.; Liau J.-Y.; Tsai J.-H.; Lin Y.-J.; Chen C.-C.; Chen Y.-C.; Chang S.-C.; Wu U.-I. |
| 臺大學術典藏 |
2021-09-17T05:56:11Z |
Factors Associated with Lung Function Decline in Patients with Non-Tuberculous Mycobacterial Pulmonary Disease
|
Lee M.-R.; Yang C.-Y.; Chang K.-P.; LI-TA KENG; Yen D.H.-T.; Wang J.-Y.; Wu H.-D.; Lee L.-N.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T05:56:11Z |
Risk factors for Mycobacterium chelonae-abscessus pulmonary disease persistence and deterioration
|
Lee M.-R.; LI-TA KENG; Shu C.-C.; Lee S.-W.; Lee C.-H.; Wang J.-Y.; Lee L.-N.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-09-17T05:56:10Z |
Diagnostic role of inflammatory and anti-inflammatory cytokines and effector molecules of cytotoxic T lymphocytes in tuberculous pleural effusion
|
Shu C.-C.; Wang J.-Y.; Hsu C.-L.; LI-TA KENG; Tsui K.; Lin J.-F.; Lai H.-C.; Yu C.-J.; Lee L.-N.; Luh K.-T. |
| 臺大學術典藏 |
2021-09-17T05:56:10Z |
Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy
|
LI-TA KENG; Shu C.-C.; Chen J.Y.P.; Liang S.-K.; Lin C.-K.; Chang L.-Y.; Chang C.-H.; Wang J.-Y.; Yu C.-J.; Lee L.-N. |
| 臺大學術典藏 |
2021-09-17T05:56:03Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; LI-TA KENG; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T05:56:02Z |
Establishing aspergillus-specific igg cut-off level for chronic pulmonary aspergillosis diagnosis: Multicenter prospective cohort study
|
Lee M.-R.; Huang H.-L.; LI-TA KENG; Chang H.-L.; Sheu C.-C.; Fu P.-K.; Wang J.-Y.; Chong I.-W.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T05:41:27Z |
Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan
|
Lee M.-R.; Ho C.-M.; Lee C.-H.; Lee M.-C.; Chang L.-Y.; KAI-LUN YU; Ko J.-C.; Wang J.-Y.; Wang J.-T.; Lee L.-N. |
| 臺大學術典藏 |
2021-09-17T05:41:25Z |
Outcome of stage IV cancer patients receiving in-hospital cardiopulmonary resuscitation: a population-based cohort study
|
Lee M.-R.; KAI-LUN YU; Kuo H.-Y.; Liu T.-H.; Ko J.-C.; Tsai J.-S.; Wang J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:20Z |
Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy
|
Keng L.-T.; Shu C.-C.; Chen J.Y.P.; SHENG-KAI LIANG; Lin C.-K.; Chang L.-Y.; Chang C.-H.; Wang J.-Y.; Yu C.-J.; Lee L.-N. |
| 臺大學術典藏 |
2021-09-17T03:21:16Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T02:51:09Z |
Risk factors for Mycobacterium chelonae-abscessus pulmonary disease persistence and deterioration
|
MENG-RUI LEE; Keng L.-T.; Shu C.-C.; Lee S.-W.; Lee C.-H.; Wang J.-Y.; Lee L.-N.; Yu C.-J.; Yang P.-C. |
